Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Eliezer Mendel Van Allen"'
Autor:
David Dewei Yang, Jiaming Huang, Jett Crowdis, Irbaz Bin Riaz, Micah Rickles-Young, Junko Tsuji, Carrie Cibulskis, Mark Fleharty, Bridget Whelpley, Kaitlin Kelleher, Julie Fishman, Brendan Michael Reardon, Jihye Park, Franklin W. Huang, Eliezer Mendel Van Allen, Atish Dipankar Choudhury
Publikováno v:
Journal of Clinical Oncology. 41:203-203
203 Background: Radium-223 (Ra-223) is a bone-seeking alpha emitter that induces double-stranded DNA breaks, and the homologous recombination (HR) pathway is critical for repairing these breaks. While prior studies suggested that metastatic castrate-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a298961a0b8a0bb949f64ce855d4a5a
https://doi.org/10.1200/jco.2023.41.6_suppl.203
https://doi.org/10.1200/jco.2023.41.6_suppl.203
Autor:
David James McConkey, Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat A. Al-Ahmadie, Jonathan E. Rosenberg, Jack Mountain, Ashley Marie Regazzi, Megan Fong, Gopa Iyer, Eliezer Mendel Van Allen, Kent William Mouw, Yujia Wen, Linda McCart, Karla V. Ballman, Himisha Beltran, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 40:4562-4562
4562 Background: Our previous work showed that basal tumors were associated with the best clinical outcomes in a Phase 2 clinical trial of neoadjuvant dose-dense MVAC plus B, and in other work we showed that basal tumors were enriched with hypoxia-as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caf320f71065342fa8c450463c1039a4
https://doi.org/10.1200/jco.2022.40.16_suppl.4562
https://doi.org/10.1200/jco.2022.40.16_suppl.4562
Autor:
Gopa Iyer, Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat A. Al-Ahmadie, Jack Mountain, Ashley Marie Regazzi, Megan Fong, Kent William Mouw, Eliezer Mendel Van Allen, David James McConkey, Yujia Wen, Linda McCart, Karla V. Ballman, Himisha Beltran, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 40:4521-4521
4521 Background: Platinum-based chemotherapy is the standard 1st-line therapy for metastatic urothelial cancer (mUC). C90601 was a randomized phase III trial testing gemcitabine and cisplatin (GC) with bevacizumab (B) or placebo (P) in patients (pts)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53e96ec49863e663cf6b742e88252bf6
https://doi.org/10.1200/jco.2022.40.16_suppl.4521
https://doi.org/10.1200/jco.2022.40.16_suppl.4521
Autor:
Renee Maria Saliby, Tejas Jammihal, Chris Labaki, Wanling Xie, Robert J. Motzer, Thomas Powles, Brian I. Rini, Laurence Albiges, Sumanta K. Pal, Rana R. McKay, Sabina Signoretti, Sachet A. Shukla, Eliezer Mendel Van Allen, David A. Braun, Toni K. Choueiri
Publikováno v:
Journal of Clinical Oncology. 40:4531-4531
4531 Background: Vascular endothelial growth factor (VEGF) and immune checkpoint inhibitors (IO) combinations are a standard in mRCC. Molecular clusters of patients have been identified and correlated with outcomes in the phase 3 IMmotion151 (IM151)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49827a6a848bd839626664ae3803b99d
https://doi.org/10.1200/jco.2022.40.16_suppl.4531
https://doi.org/10.1200/jco.2022.40.16_suppl.4531
Publikováno v:
Journal of Clinical Oncology. 40:3015-3015
3015 Background: The clinical care of oncology patients is routinely informed by tumor and inherited genetic profiles. This is accomplished by molecular pathologists synthesizing the growing body of clinical guidelines and scientific evidence that as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd95e99108e39e08ed4452e29985aa50
https://doi.org/10.1200/jco.2022.40.16_suppl.3015
https://doi.org/10.1200/jco.2022.40.16_suppl.3015
Autor:
Seyram Adjoa Doe-Tetteh, Sabrina Yvonne Camp, Jett Crowdis, Anne Marie Noronha, Dalicia Reales, Tina Alano, Agnes Viale, Mark Donoghue, Nicholas D. Socci, Michael F. Berger, Hikmat A. Al-Ahmadie, Samuel Aaron Funt, Darren R. Feldman, Eli L. Diamond, Eliezer Mendel Van Allen, David B. Solit
Publikováno v:
Journal of Clinical Oncology. 40:6532-6532
6532 Background: Tumor genomic profiling is increasingly used to identify actionable genomic alterations as a guide to therapy selection. To overcome barriers to genomic testing for patients with rare cancers, we initiated a program to offer free cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c4b35602511d1a553cf6b813f4f2430
https://doi.org/10.1200/jco.2022.40.16_suppl.6532
https://doi.org/10.1200/jco.2022.40.16_suppl.6532
Autor:
Chris Labaki, Long Zhang, Yue Hou, Kevin Bi, Charbel Hobeika, Ziad Bakouny, Sabrina Yvonne Camp, Carmen Priolo, Damir Khabibullin, Nicholas Schindler, Michel Alchoueiry, Thomas Denize, Renee Maria Saliby, Sayed Matar, Sabina Signoretti, Eliezer Mendel Van Allen, Sachet A. Shukla, David A. Braun, Elizabeth Henske, Toni K. Choueiri
Publikováno v:
Journal of Clinical Oncology. 40:4549-4549
4549 Background: ChRCC represents about 5% of all kidney cancer and has a dismal prognosis in the metastatic setting, with limited response to immune checkpoint inhibitors (ICI) and targeted therapy. We evaluated the molecular properties of ChRCC and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a35c01812d9bbd52601de94e2e329e5
https://doi.org/10.1200/jco.2022.40.16_suppl.4549
https://doi.org/10.1200/jco.2022.40.16_suppl.4549
Autor:
Atish Dipankar Choudhury, Wanling Xie, Alok Tewari, David Tomoaki Miyamoto, Bose Kochupurakkal, Leigh Ellis, Matthew Bandel, Claire Leisner, Geoffrey Shapiro, Alan D. D'Andrea, Eliezer Mendel Van Allen, Matthew Freedman, Myles Brown, Mary-Ellen Taplin, Himisha Beltran
Publikováno v:
Journal of Clinical Oncology. 40:TPS5098-TPS5098
TPS5098 Background: Enhancer of zeste homolog 2 (EZH2) is frequently overexpressed in metastatic castration-resistant prostate cancer (mCRPC), and is linked to lineage plasticity and therapy resistance. In pre-clinical studies, EZH2 directly regulate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34152fe0e6a460e52cfcd29e9c201d40
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5098
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5098
Autor:
Bradley Alexander McGregor, Wanling Xie, Mehmet Asim Bilen, Matthew T Campbell, Amir Mortazavi, Jiaming Huang, Rajitha Sunkara, Praful Ravi, Amishi Yogesh Shah, Sylvan Baca, Guru P. Sonpavde, Joaquim Bellmunt, Arlene O. Siefker-Radtke, Sabina Signoretti, Eliezer Mendel Van Allen, Himisha Beltran, Rana R. McKay, Toni K. Choueiri
Publikováno v:
Journal of Clinical Oncology. 40:569-569
569 Background: Patients with metastatic genitourinary malignancies with neuroendocrine have limited therapeutic options following platinum therapy. Given encouraging results in initial cohort analysis for small cell urinary tract carcinoma, a cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f50ee10c15e633e1e087a325a281d12f
https://doi.org/10.1200/jco.2022.40.6_suppl.569
https://doi.org/10.1200/jco.2022.40.6_suppl.569
Autor:
Atish Dipankar Choudhury, Wanling Xie, Alok Tewari, David Tomoaki Miyamoto, Bose Kochupurakkal, Leigh Ellis, Matthew Bandel, Claire Leisner, Geoffrey Shapiro, Alan D. D'Andrea, Eliezer Mendel Van Allen, Matthew Freedman, Mary-Ellen Taplin, Himisha Beltran
Publikováno v:
Journal of Clinical Oncology. 40:TPS195-TPS195
TPS195 Background: Enhancer of zeste homolog 2 (EZH2) is frequently overexpressed in metastatic castration-resistant prostate cancer (mCRPC), and is linked to lineage plasticity and therapy resistance. In pre-clinical studies, EZH2 directly regulates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80b0b2011a6bb6ca054bf0c3fe570613
https://doi.org/10.1200/jco.2022.40.6_suppl.tps195
https://doi.org/10.1200/jco.2022.40.6_suppl.tps195